Hepatocellular carcinoma and vitamin D: A review

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 11, 2011, Pages 1597-1603

  Chiang, Kun Chun ^a   Yeh, Chun Nan ^a   Chen, Miin Fu ^a   Chen, Tai C ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; Polymorphism; Steroid hormone; Vitamin D

Indexed keywords

1 ALPHA,25 DIHYDROXYVITAMIN D2; 20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; ANTIESTROGEN; ANTINEOPLASTIC AGENT; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; ESTROGEN; INTERFERON; INTERLEUKIN 2; OCTREOTIDE; PROTEIN KINASE C; SEOCALCITOL; SOMATOMEDIN B; SOMATOMEDIN C; SORAFENIB; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; COLORECTAL TUMOR; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL RATE; VITAMIN D METABOLISM;

EID: 80054881171     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06892.x     Document Type: Review

References (75)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int. J. Cancer 2001; 94: 153-6.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
3. Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J. Gastroenterol. Hepatol. 2010; 25: 439-52.
4. Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg. Clin. North Am. 2010; 90: 803-16.
5. Okuda K. Epidemiology of primary liver cancer. In: Tobe T, ed. Primary Liver Cancer in Japan. Tokyo: Springer-Verlag, 1992; 3-15.
6. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann. Surg. 2009; 249: 20-5.
7. Tsuzuki T, Sugioka A, Ueda M etal. Hepatic resection for hepatocellular carcinoma. Surgery 1990; 107: 511-20.
8. Sangiovanni A, Del Ninno E, Fasani P etal. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-14.
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
10. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002; 3: 593-603.
11. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 2007; 27: 55-76.
12. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
13. Holick MF. Vitamin D: a millenium perspective. J. Cell. Biochem. 2003; 88: 296-307.
14. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim. Biophys. Acta 2011; 1814: 186-99.
15. Townsend K, Banwell CM, Guy M etal. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer Res. 2005; 11: 3579-86.
16. Zehnder D, Bland R, Williams MC etal. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001; 86: 888-94.
17. Chiang KC, Chen TC. Vitamin D for the prevention and treatment of pancreatic cancer. World J. Gastroenterol. 2009; 15: 3349-54.
18. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542-8.
19. Haussler MR, Haussler CA, Jurutka PW etal. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J. Endocrinol. 1997; 154 (Suppl.): S57-73.
20. Ramagopalan SV, Heger A, Berlanga AJ etal. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010; 20: 1352-60.
21. 3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188-90.
22. Adams JS, Hewison M. Update in vitamin D. J. Clin. Endocrinol. Metab. 2010; 95: 471-8.
23. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004; 80: 1678S-88S.
24. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab. 2003; 14: 423-30.
25. 3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res. 2009; 29: 3547-53.
26. 3 on liver cancer cells. Anticancer Res. 2009; 29: 3591-6.
27. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994; 63: 451-86.
28. Haussler MR, Whitfield GK, Haussler CA etal. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 1998; 13: 325-49.
29. Tagami T, Lutz WH, Kumar R, Jameson JL. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem. Biophys. Res. Commun. 1998; 253: 358-63.
30. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128: 707-19.
31. Dong X, Lutz W, Schroeder TM etal. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 16007-12.
32. MacDonald PN, Dowd DR, Zhang C, Gu C. Emerging insights into the coactivator role of NCoA62/SKIP in Vitamin d-mediated transcription. J. Steroid Biochem. Mol. Biol. 2004; 89-90: 179-86.
33. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat. Rev. Mol. Cell Biol. 2003; 4: 46-56.
34. 3 in vivo and in vitro. Mol. Endocrinol. 2004; 18: 2660-71.
35. Bettoun DJ, Buck DW 2nd, Lu J, Khalifa B, Chin WW, Nagpal S. A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J. Biol. Chem. 2002; 277: 24847-50.
36. Shah S, Islam MN, Dakshanamurthy S etal. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol. Cell. 2006; 21: 799-809.
37. 3. Cancer Lett. 2000; 151: 97-102.
38. Caputo A, Pourgholami MH, Akhter J, Morris DL. 1, 25-Dihydroxyvitamin D(3) induced cell cycle arrest in the human primary liver cancer cell line HepG2. Hepatol. Res. 2003; 26: 34-9.
39. 3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 2001; 121: 103-9.
40. 3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997; 15: 1555-63.
41. 3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin. Cancer Res. 2003; 9: 2350-6.
42. 3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J. Surg. 2001; 71: 414-17.
43. Luo WJ, Chen JY, Xu W, Zhao F, Chen YM, Shen XF. Effects of vitamin D analogue EB1089 on proliferation and apoptosis of hepatic carcinoma cells. Zhonghua Yu Fang Yi Xue Za Zhi 2004; 38: 415-18.
44. 3 analogs as therapeutic agents for prostate cancer. J. Steroid Biochem. Mol. Biol. 2007; 103: 717-20.
45. Ghous Z, Akhter J, Pourgholami MH, Morris DL. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res. 2008; 28: 3757-61.
46. Sahpazidou D, Stravoravdi P, Toliou T etal. Significant experimental decrease of the hepatocellular carcinoma incidence in C3H/Sy mice after long-term administration of EB1089, a vitamin D analogue. Oncol. Res. 2003; 13: 261-8.
47. Liu G, Oettel K, Ripple G etal. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin. Cancer Res. 2002; 8: 2820-7.
48. Liu G, Wilding G, Staab MJ etal. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin. Cancer Res. 2003; 9: 4077-83.
49. Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol. Aspects Med. 2008; 29: 433-52.
50. Protiva P, Cross HS, Hopkins ME etal. Chemoprevention of colorectal neoplasia by estrogen: potential role of vitamin D activity. Cancer Prev Res (Phila) 2009; 2: 43-51.
51. 3 in lipiodol: pilot study in patients with hepatocellular carcinoma. Int. J. Oncol. 2002; 21: 901-6.
52. Nagubandi S, Kumar R, Londowski JM, Corradino RA, Tietz PS. Role of vitamin D glucosiduronate in calcium homeostasis. J. Clin. Invest. 1980; 66: 1274-80.
53. 3. J. Clin. Invest. 1980; 65: 277-84.
54. 3 in rat bile. Arch. Biochem. Biophys. 1980; 205: 175-9.
55. Dalhoff K, Dancey J, Astrup L etal. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 2003; 89: 252-7.
56. Baker AR, McDonnell DP, Hughes M etal. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 3294-8.
57. Miyamoto K, Kesterson RA, Yamamoto H etal. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol. Endocrinol. 1997; 11: 1165-79.
58. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-56.
59. Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 10529-34.
60. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int. J. Epidemiol. 1990; 19: 820-4.
61. Tang C, Chen N, Wu M, Yuan H, Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res. Treat. 2009; 117: 391-9.
62. Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009; 29: 3511-36.
63. Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA. Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. J. Steroid Biochem. Mol. Biol. 2004; 89-90: 187-93.
64. Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 2335-9.
65. Falleti E, Bitetto D, Fabris C etal. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J. Gastroenterol. 2010; 16: 3016-24.
66. Huang YW, Liao YT, Chen W etal. Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun. 2010; 11: 87-93.
67. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 2001; 116: 838-45.
68. Jeng KS, Sheen IS, Wang YC etal. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J. Gastroenterol. 2004; 10: 643-8.
69. Ito Y, Takeda T, Sakon M etal. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 2001; 84: 1377-83.
70. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007; 7: 684-700.
71. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res. 2006; 66: 8565-73.
72. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int. J. Cancer 1999; 81: 730-3.
73. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 2007; 14: 1835-45.
74. Okumoto K, Hattori E, Tamura K etal. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 2004; 24: 21-8.
75. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol. Pathol. 2001; 54: 138-44.